| Title |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, December 2013
|
| DOI | 10.1007/s00432-013-1565-3 |
| Pubmed ID | |
| Authors |
Roxana Magaña-Maldonado, Karen Manoutcharian, Norma Y. Hernández-Pedro, Edgar Rangel-López, Verónica Pérez-De la Cruz, César Rodríguez-Balderas, Julio Sotelo, Benjamín Pineda |
| Abstract |
Glioblastoma multiforme is the most frequent primary brain tumor, it has poor prognosis, and it remains refractory to current treatment. The success of temozolomide (TMZ) appears to be limited by the occurrence of chemoresistance. Recently, we report the use of pertussis toxin as adjuvant immunotherapy in a C6 glioma model; showing a decrease in tumoral size, it induced selective cell death in Treg cells, and it elicited less infiltration of tumoral macrophages. Here, we evaluated the cytotoxic effect of pertussis toxin in combination with TMZ for glioma treatment, both in vitro and in vivo RG2 glioma model. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 7% |
| Unknown | 25 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 44% |
| Student > Bachelor | 2 | 7% |
| Other | 1 | 4% |
| Librarian | 1 | 4% |
| Student > Ph. D. Student | 1 | 4% |
| Other | 3 | 11% |
| Unknown | 7 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 5 | 19% |
| Biochemistry, Genetics and Molecular Biology | 4 | 15% |
| Agricultural and Biological Sciences | 4 | 15% |
| Medicine and Dentistry | 3 | 11% |
| Social Sciences | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 9 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 December 2013.
All research outputs
#19,221,261
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#1,814
of 2,632 outputs
Outputs of similar age
#237,505
of 312,391 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#13
of 16 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,391 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.